Diagnostic Development Division
Diagnostic Division of Acert Biotech is involved in developing kit for various infectious diseases with great passion. We are implementing our noble and innovative ideas to develop cost-effective and more precise and specific diagnostic kit for life threatening infectious diseases.
Dr. Mahalakshmi N is the in-charge of diagnostic kit development division. She is a specialist in molecular biology from her PG degree onwards. She has included immunotechnology as one of her domain by working on validating the efficacy of vaccine candidates for infectious disease lymphatic filariasis or elephantiasis. Further, in her tenure as Research Scientist of DBT-BUILDER program, she worked to enhance the reactivity of Ag-Ab by by fine-tuning and tinkering with immunoassays for the detection of lymphatic filariasis and transferred the technology to a company for validation. She is well well-experienced to produce the antigen in E.coli by rDNA technology, scale up the production and purity the recombinant antigen. Also, she can produce monoclonal antibodies against these antigens and devise immunological assays like ELISA. Additionally, she has experience in evolving either Ag or Ab to augment the reactivity and specificity of Ag-Ab interactions with minimal cross-reactivity.
Drug Formulation and Delivery Division
Drug formulation and Delivery division is basically involved in formulation of new and existing drug molecules for better outcome by green synthesis. Nano-drug development is our thirst area of research. We are also developing noble delivery strategies for target-specific drug delivery.
Dr. Jaison Jeevanandam has experience in nanoparticle synthesis, especially in green synthesis using plant extracts,
characterization, cytotoxic analysis of nanoparticles, and also in vitro diabetic models. His current research focuses on the application of bionanotechnology in the fabrication of nanoformulation to deliver drugs for the treatment of several diseases, especially diabetes. He is also working with some researchers from United States on certain projects for cancer theranostics using molecular dynamics. He has authored about 16 book chapters, 30 journal articles and edited a book on ˜Research advances in dynamic light scattering, Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications, ”The Role of Molecular Dynamics Simulation.
Biologic Development Division
Biologics Development Division has made remarkable advancement in developing noble idea in the designing and development of novel biologics for many diseases. Our plan is to develop affordable and better vaccine candidates and antibody-based biologics to various diseases.
Dr. Paul is an experienced scientist in development of vaccine candidates and antibody-based biologics. He has worked on E. coli and Pichia expression system for recombinant protein. Moreover, he is also involved in biotechnology product development and has vast experience in evaluation of potential antigen candidates for diagnosis and therapeutics. He also involved in development of biologic product.